FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.
What happened
FDA inspected the Dallas fertility center from June 6, 2025, to June 13, 2025. It found that donor medical history forms did not ask about all risk factors for communicable diseases, some donors were marked eligible despite risk factors or before test results arrived, and test specimens were sometimes collected outside the allowed time window. FDA also said the center's written procedures and donor records were incomplete, including a repeat violation from a 2021 inspection.
What FDA found
The donor medical history form lacked required questions or timeframes for hepatitis B and C, West Nile virus, syphilis, tattoo/piercing sterility, military residence in Europe, and blood transfusion in France.
21 CFR 1271.75(a)(1)The center marked donors eligible even when their answers showed risk factors for communicable disease.
21 CFR 1271.75(d)The center determined donor eligibility before receiving required disease test results.
21 CFR 1271.50(a)The center sometimes collected the donor test specimen outside the allowed period of up to seven days before or after cell or tissue collection.
21 CFR 1271.80(b)Donor record summaries omitted the reasons for ineligibility for at least 21 directed semen donors and did not list and interpret all required test results.
21 CFR 1271.55(b)(2), (b)(4)Written procedures for screening, testing, and determining donor eligibility were incomplete, and FDA noted this was a repeat violation from 2021.
21 CFR 1271.47(a)
What FDA wants
FDA tells the company to correct the violations, prevent recurrence, and respond in writing within 15 working days with specific steps and documentation. It also says HCT/Ps from donors with incomplete screening or testing must stay in quarantine unless FDA grants an exemption, with a separate labeling path for embryos.
Who should pay attention
- fertility clinics that use donor oocytes or semen
- reproductive tissue banks and donor programs
- patients receiving donor gametes or embryos
This is a summary. Read the original letter on fda.gov.